<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02413047</url>
  </required_header>
  <id_info>
    <org_study_id>1502834262</org_study_id>
    <nct_id>NCT02413047</nct_id>
  </id_info>
  <brief_title>Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator</brief_title>
  <official_title>A Pilot Study to Evaluate if Response to Infliximab or Adalimumab May be Regained With the Addition of an Immunomodulator</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The immunogenicity of anti-tumor necrosis factor alpha (anti-TNF) therapy in inflammatory
      bowel disease (IBD) is an important cause of loss of response to therapy that may lead to
      escalation of dose or discontinuation of therapy. Antibodies may develop to infliximab (ATI)
      or to adalimumab (ATA) and cause this loss of response, also known as a secondary loss of
      response. An alternative approach is the addition of immunomodulator (IM) therapy to
      counteract the antibody response and regain efficacy of the biologic medication. The
      investigators' goal is to treat patients' who have lost response to adalimumab or infliximab
      with an immunomodulator with the goal of eliminating the circulating antibodies to the
      anti-TNF and restoring efficacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The immunogenicity of anti-tumor necrosis factor alpha (anti-TNF) therapy in inflammatory
      bowel disease (IBD) is an important cause of loss of response to therapy that may lead to
      escalation of dose or discontinuation of therapy. Antibodies may develop to infliximab (ATI)
      or to adalimumab (ATA) and cause this loss of response, also known as a secondary loss of
      response. In an attempt to overcome these antibodies, dose escalation can be accomplished
      either by increasing the dose or shortening the interval between doses. The ability of dose
      escalation to overcome loss of response due to the presence of ATI or ATA remains
      controversial. Escalation of dose increases the cost of therapy substantially. If the
      decision is made to discontinue therapy after a secondary loss of response, a clinician may
      choose to switch to an alternate anti-TNF therapy of which there are currently only four.
      Loss of response to one agent predicts a lesser response to other anti-TNF agents and with a
      limited number of therapeutic options the goal should be to optimize therapy rather than to
      discontinue therapy.

      An alternative approach is the addition of immunomodulator (IM) therapy to counteract the
      antibody response and regain efficacy of the biologic medication. Three such IMs known to be
      effective in the treatment of IBD are azathioprine (AZA), 6-mercaptopurine (6MP) and
      methotrexate (MTX). The SONIC trial showed that patients on infliximab and azathioprine only
      developed antibodies at 4% of the time as opposed to those on infliximab monotherapy who
      formed ATI at 13%. The same principal was shown during the COMMIT trial in which patients on
      infliximab alone had ATI at a rate of 20% versus 4% on methotrexate plus infliximab.
      Ben-Horin et al. reported five patients treated initially with infliximab monotherapy whom
      had secondary loss of response based on clinical symptoms. These patients had ATI and all had
      undetectable troughs of infliximab. In all five patients ATI became undetectable, an adequate
      trough level was restored and the patients regained clinical response with the addition of an
      immunomodulator. Combination therapy with azathioprine and infliximab has led to a higher
      percentage of patients in steroid free remission than either drug alone. Our goal is to treat
      patients' who have lost response to adalimumab or infliximab with an immunomodulator with the
      goal of eliminating the circulating antibodies to the anti-TNF and restoring efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    physician decision to stop study early due to low enrollment
  </why_stopped>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Harvey Bradshaw Index HBI: Decrease &gt;3 Points or Remission Score&lt;5</measure>
    <time_frame>4 months</time_frame>
    <description>The Harvey-Bradshaw index (HBI) is a simplified version of the CDAI to foster a systematic collection of clinical data related to Crohn's disease.
The index considers five parameters, exclusively clinical; patient well-being, abdominal pain, number of liquid or soft stools, abdominal mass, and complications.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Therapeutic Trough Level for Infliximab is Defined as &gt;3 and as &gt; 5 for Adalimumab.</measure>
    <time_frame>4 months</time_frame>
    <description>Trough level is the lowest level of drug detected in a subject prior to next dose of medication</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ulcerative Colitis Clinical Score UCCS Decrease &gt;3 Points or Remission Score &lt;3</measure>
    <time_frame>4 months</time_frame>
    <description>UCCS is the ulcerative colitis clinical score which is based on disease activity. The score is based on bowel movements, blood in stool, overall well being, and global assessment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change Inflammatory Bowel Disease Questionnaire SIBDQ</measure>
    <time_frame>4 months</time_frame>
    <description>SIBDQ is the short inflammatory bowel disease questionnaire which is a health-related quality of life tool measuring physical, social, and emotional status.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Eliminate Antibodies: Threshold Levels for ATI is &lt; 3.1and is &lt; 1.7 for ADA.</measure>
    <time_frame>4 months</time_frame>
    <description>unwanted immunogenicity is an immune response by an organism against a therapeutic antigen. This reaction leads to production of anti-drug antibodies inactivating the therapeutic effects of the treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement or Normalization of Mayo Endoscopy Score for UC Patients</measure>
    <time_frame>4 months</time_frame>
    <description>Mayo endoscopy score is scoring completed during the endoscopy to evaluate disease activity. Scoring is based on stool frequency, rectal bleeding, mucosal appearance at endoscopy, and physician rating of disease activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement or Normalization of C-reactive Protein, Sedimentation Rate and Fecal Calprotectin</measure>
    <time_frame>4 months</time_frame>
    <description>c-reactive protein, sedimentation rate, and fecal calprotectin were collected to monitor the level of inflammation in the subject. Improvement was determined if inflammation level was reduced.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement or Normalization of the Simple Endoscopic Score-Crohn's Disease (SES-CD)</measure>
    <time_frame>4 months</time_frame>
    <description>SESCD is the simple endoscopic score for crohn's disease patients scored during endoscopy. The scoring is based on appearance of ulcers/sizing, % of ulcerative surface, % of affected surface, and if there were any narrowings or strictures found.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Inflammatory Bowel Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Immunomodulator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azathioprine, 6 mercaptopurine or methotrexate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azathioprine</intervention_name>
    <description>Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past.</description>
    <arm_group_label>Immunomodulator</arm_group_label>
    <other_name>Imuran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6 mercaptopurine</intervention_name>
    <description>Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past as an alternative to imuran</description>
    <arm_group_label>Immunomodulator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Medication will be given in subcutaneous injection form once a week if the patient cannot take imuran or 6 mercaptopurine.</description>
    <arm_group_label>Immunomodulator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with inflammatory bowel disease who on are stable doses of infliximab or
             adalimumab for at least 3 months who experience a secondary loss of response to the
             medication based on clinical symptoms.

          -  Presence of at least one objective marker of active disease: active disease based on
             endoscopy, elevated fecal calprotectin or serologic markers of inflammation
             (C-reactive protein or sedimentation rate).

          -  Crohn's patients have a Harvey Bradshaw index &gt;5

          -  Ulcerative colitis patients have a Ulcerative Colitis Clinical Score &gt; 5

          -  Have an undetectable or inadequate trough level of infliximab or adalimumab and
             detectable ATI or ADA.

          -  Oral corticosteroid therapy is allowed. (prednisone at a stable dose ≤30 mg/day,
             budesonide at a stable dose ≤9 mg/day, or equivalent steroid) provided that the dose
             has been stable for the 4 weeks immediately prior to enrollment if corticosteroids
             have recently been initiated

        Exclusion Criteria:

          -  Previous noncompliant with medications

          -  &lt; 18 years of age or &gt;80 years of age.

          -  Congestive heart failure

          -  Abnormal liver tests alanine aminotransferase (ALT) or aspartate aminotransferase
             (AST) 2 × the upper limit of normal (ULN) or leucopenia WBC count &lt;3 × 109/L

          -  Pregnant or planning on becoming pregnant.

          -  Active tuberculosis or hepatitis B infection

          -  Any cancer within the past 5 years. (Exception non-melanomatous skin cancer.)

          -  Receiving any immunomodulator therapy within the past 3 months

          -  Evidence of or treatment for C. difficile infection within 60 days or other intestinal
             pathogen within 30 days prior to enrollment

          -  Clinically significant extra-intestinal infection (e.g., pneumonia, pyelonephritis)
             within 30 days of the initial screening visit

          -  Any live vaccinations within 30 days prior to study drug administration except for the
             influenza vaccine

          -  Any identified congenital or acquired immunodeficiency (e.g., common variable
             immunodeficiency, human immunodeficiency virus [HIV] infection, organ transplantation)

          -  Any unstable or uncontrolled cardiovascular, pulmonary, hepatic, renal,
             endocrine/metabolic, or other medical disorder that, in the opinion of the
             investigator, would confound the study results or compromise patient safety

          -  Unable to give own informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Bohm, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>IndianaU IRB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 6, 2015</study_first_submitted>
  <study_first_submitted_qc>April 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2015</study_first_posted>
  <results_first_submitted>September 19, 2019</results_first_submitted>
  <results_first_submitted_qc>October 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 4, 2019</results_first_posted>
  <last_update_submitted>October 15, 2019</last_update_submitted>
  <last_update_submitted_qc>October 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Matthew Bohm</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Mercaptopurine</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No individual participant data was analyzed</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 12, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT02413047/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Immunomodulator</title>
          <description>Azathioprine, 6 mercaptopurine or methotrexate.
Azathioprine: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past.
6 mercaptopurine: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past as an alternative to imuran
Methotrexate: Medication will be given in subcutaneous injection form once a week if the patient cannot take imuran or 6 mercaptopurine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants on Infliximab</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants on Adalimumab</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Not enough study participants enrolled for data analysis</population>
      <group_list>
        <group group_id="B1">
          <title>Immunomodulator</title>
          <description>Azathioprine, 6 mercaptopurine or methotrexate.
Azathioprine: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past.
6 mercaptopurine: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past as an alternative to imuran
Methotrexate: Medication will be given in subcutaneous injection form once a week if the patient cannot take imuran or 6 mercaptopurine.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Disease</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.66666667" lower_limit="4" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>White Blood Cell Count (WBC)</title>
          <units>x 10^3 cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.566666667" lower_limit="6.2" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin</title>
          <units>gm/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.63" lower_limit="12.6" upper_limit="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Platelet Count</title>
          <units>x 10^3 cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="256.00" lower_limit="237" upper_limit="292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aspartate Aminotransferase</title>
          <units>units/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.00" lower_limit="16" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ALT</title>
          <units>units/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.67" lower_limit="13" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bilirubin</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.67" lower_limit="0.60" upper_limit="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Albumin</title>
          <units>gm/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.37" lower_limit="4.10" upper_limit="4.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alkaline Phosphatase</title>
          <units>units/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93.33" lower_limit="66" upper_limit="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Above-Normal C-Reactive Protein</title>
          <description>'Normal&quot; c-reactive protein levels are resulted as &lt;0.5mg/dL</description>
          <population>&quot;Normal&quot; c-reactive protein levels are resulted from the laboratory as '&lt;0.5mg/dL'. Therefore, only levels higher than 0.5mg/dL will be reported.</population>
          <units>mg/dL</units>
          <param>Number</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Erythrocyte Sedimentation Rate</title>
          <units>mm/hr</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.67" lower_limit="15" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Calprotectin</title>
          <units>mCg/gm</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="331.50" lower_limit="232" upper_limit="431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Simple Endoscopic Score for Crohn's Disease</title>
          <description>0-2 = remission 3-6 = mild endoscopic activity 7-15 = moderate endoscopic activity &gt;15 = severe endoscopic activity</description>
          <units>points</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.67" lower_limit="6.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Harvey Bradshaw Index (HBI) Score</title>
          <description>&lt;5 = Remission 5-7 = mild activity 8-16 = moderate activity &gt;16 = severe activity</description>
          <units>points</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.67" lower_limit="3" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Short Inflammatory Bowel Disease Questionnaire</title>
          <description>SIBDQ measure the quality of life in patients with IBD. Each question is graded from 1-7. outcomes vary with '32' (very poor quality of life) to 224 (perfect quality of life. Patients in systematic remission typically have a score of 170 or greater. An increase of 16-32 points constitutes clinically meaningful improvement.</description>
          <units>points</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.00" lower_limit="28" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Infliximab concentration</title>
          <description>Trough Level: lowest level of drug detected in subjected prior to next dose.</description>
          <population>Only 2 subjects of 3 subjects were on infliximab for the study. 1 of the 2 subjects had a undetectable trough level (&lt;1) and the other subject level was 6.3.</population>
          <units>ug/mL</units>
          <param>Number</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Antibodies to Infliximab concentration</title>
          <population>2 of the 3 subjects were on infliximab</population>
          <units>units/mL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.70" lower_limit="18.5" upper_limit="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Adalimumab concentration</title>
          <description>Trough level: lowest level of drug detected in subject prior to next dose</description>
          <population>1 of the 3 subjects were on adalimumab</population>
          <units>ug/mL</units>
          <param>Number</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Antibodies to Adalimumab concentration</title>
          <population>1 of 3 subjects on Adalimumab</population>
          <units>units/mL</units>
          <param>Number</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Harvey Bradshaw Index HBI: Decrease &gt;3 Points or Remission Score&lt;5</title>
        <description>The Harvey-Bradshaw index (HBI) is a simplified version of the CDAI to foster a systematic collection of clinical data related to Crohn's disease.
The index considers five parameters, exclusively clinical; patient well-being, abdominal pain, number of liquid or soft stools, abdominal mass, and complications.</description>
        <time_frame>4 months</time_frame>
        <population>Not enough subjects for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Immunomodulator</title>
            <description>Azathioprine, 6 mercaptopurine or methotrexate.
Azathioprine: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past.
6 mercaptopurine: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past as an alternative to imuran
Methotrexate: Medication will be given in subcutaneous injection form once a week if the patient cannot take imuran or 6 mercaptopurine.</description>
          </group>
        </group_list>
        <measure>
          <title>Harvey Bradshaw Index HBI: Decrease &gt;3 Points or Remission Score&lt;5</title>
          <description>The Harvey-Bradshaw index (HBI) is a simplified version of the CDAI to foster a systematic collection of clinical data related to Crohn's disease.
The index considers five parameters, exclusively clinical; patient well-being, abdominal pain, number of liquid or soft stools, abdominal mass, and complications.</description>
          <population>Not enough subjects for analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Therapeutic Trough Level for Infliximab is Defined as &gt;3 and as &gt; 5 for Adalimumab.</title>
        <description>Trough level is the lowest level of drug detected in a subject prior to next dose of medication</description>
        <time_frame>4 months</time_frame>
        <population>Not enough subjects for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Immunomodulator</title>
            <description>Azathioprine, 6 mercaptopurine or methotrexate.
Azathioprine: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past.
6 mercaptopurine: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past as an alternative to imuran
Methotrexate: Medication will be given in subcutaneous injection form once a week if the patient cannot take imuran or 6 mercaptopurine.</description>
          </group>
        </group_list>
        <measure>
          <title>Therapeutic Trough Level for Infliximab is Defined as &gt;3 and as &gt; 5 for Adalimumab.</title>
          <description>Trough level is the lowest level of drug detected in a subject prior to next dose of medication</description>
          <population>Not enough subjects for analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ulcerative Colitis Clinical Score UCCS Decrease &gt;3 Points or Remission Score &lt;3</title>
        <description>UCCS is the ulcerative colitis clinical score which is based on disease activity. The score is based on bowel movements, blood in stool, overall well being, and global assessment.</description>
        <time_frame>4 months</time_frame>
        <population>Not enough subjects for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Immunomodulator</title>
            <description>Azathioprine, 6 mercaptopurine or methotrexate.
Azathioprine: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past.
6 mercaptopurine: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past as an alternative to imuran
Methotrexate: Medication will be given in subcutaneous injection form once a week if the patient cannot take imuran or 6 mercaptopurine.</description>
          </group>
        </group_list>
        <measure>
          <title>Ulcerative Colitis Clinical Score UCCS Decrease &gt;3 Points or Remission Score &lt;3</title>
          <description>UCCS is the ulcerative colitis clinical score which is based on disease activity. The score is based on bowel movements, blood in stool, overall well being, and global assessment.</description>
          <population>Not enough subjects for analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change Inflammatory Bowel Disease Questionnaire SIBDQ</title>
        <description>SIBDQ is the short inflammatory bowel disease questionnaire which is a health-related quality of life tool measuring physical, social, and emotional status.</description>
        <time_frame>4 months</time_frame>
        <population>Not enough subjects for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Immunomodulator</title>
            <description>Azathioprine, 6 mercaptopurine or methotrexate.
Azathioprine: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past.
6 mercaptopurine: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past as an alternative to imuran
Methotrexate: Medication will be given in subcutaneous injection form once a week if the patient cannot take imuran or 6 mercaptopurine.</description>
          </group>
        </group_list>
        <measure>
          <title>Change Inflammatory Bowel Disease Questionnaire SIBDQ</title>
          <description>SIBDQ is the short inflammatory bowel disease questionnaire which is a health-related quality of life tool measuring physical, social, and emotional status.</description>
          <population>Not enough subjects for analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Eliminate Antibodies: Threshold Levels for ATI is &lt; 3.1and is &lt; 1.7 for ADA.</title>
        <description>unwanted immunogenicity is an immune response by an organism against a therapeutic antigen. This reaction leads to production of anti-drug antibodies inactivating the therapeutic effects of the treatment.</description>
        <time_frame>4 months</time_frame>
        <population>Not enough subjects for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Immunomodulator</title>
            <description>Azathioprine, 6 mercaptopurine or methotrexate.
Azathioprine: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past.
6 mercaptopurine: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past as an alternative to imuran
Methotrexate: Medication will be given in subcutaneous injection form once a week if the patient cannot take imuran or 6 mercaptopurine.</description>
          </group>
        </group_list>
        <measure>
          <title>Eliminate Antibodies: Threshold Levels for ATI is &lt; 3.1and is &lt; 1.7 for ADA.</title>
          <description>unwanted immunogenicity is an immune response by an organism against a therapeutic antigen. This reaction leads to production of anti-drug antibodies inactivating the therapeutic effects of the treatment.</description>
          <population>Not enough subjects for analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement or Normalization of Mayo Endoscopy Score for UC Patients</title>
        <description>Mayo endoscopy score is scoring completed during the endoscopy to evaluate disease activity. Scoring is based on stool frequency, rectal bleeding, mucosal appearance at endoscopy, and physician rating of disease activity</description>
        <time_frame>4 months</time_frame>
        <population>Not enough subjects for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Immunomodulator</title>
            <description>Azathioprine, 6 mercaptopurine or methotrexate.
Azathioprine: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past.
6 mercaptopurine: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past as an alternative to imuran
Methotrexate: Medication will be given in subcutaneous injection form once a week if the patient cannot take imuran or 6 mercaptopurine.</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement or Normalization of Mayo Endoscopy Score for UC Patients</title>
          <description>Mayo endoscopy score is scoring completed during the endoscopy to evaluate disease activity. Scoring is based on stool frequency, rectal bleeding, mucosal appearance at endoscopy, and physician rating of disease activity</description>
          <population>Not enough subjects for analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement or Normalization of C-reactive Protein, Sedimentation Rate and Fecal Calprotectin</title>
        <description>c-reactive protein, sedimentation rate, and fecal calprotectin were collected to monitor the level of inflammation in the subject. Improvement was determined if inflammation level was reduced.</description>
        <time_frame>4 months</time_frame>
        <population>Not enough subjects for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Immunomodulator</title>
            <description>Azathioprine, 6 mercaptopurine or methotrexate.
Azathioprine: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past.
6 mercaptopurine: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past as an alternative to imuran
Methotrexate: Medication will be given in subcutaneous injection form once a week if the patient cannot take imuran or 6 mercaptopurine.</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement or Normalization of C-reactive Protein, Sedimentation Rate and Fecal Calprotectin</title>
          <description>c-reactive protein, sedimentation rate, and fecal calprotectin were collected to monitor the level of inflammation in the subject. Improvement was determined if inflammation level was reduced.</description>
          <population>Not enough subjects for analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement or Normalization of the Simple Endoscopic Score-Crohn's Disease (SES-CD)</title>
        <description>SESCD is the simple endoscopic score for crohn's disease patients scored during endoscopy. The scoring is based on appearance of ulcers/sizing, % of ulcerative surface, % of affected surface, and if there were any narrowings or strictures found.</description>
        <time_frame>4 months</time_frame>
        <population>Not enough subjects for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Immunomodulator</title>
            <description>Azathioprine, 6 mercaptopurine or methotrexate.
Azathioprine: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past.
6 mercaptopurine: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past as an alternative to imuran
Methotrexate: Medication will be given in subcutaneous injection form once a week if the patient cannot take imuran or 6 mercaptopurine.</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement or Normalization of the Simple Endoscopic Score-Crohn's Disease (SES-CD)</title>
          <description>SESCD is the simple endoscopic score for crohn's disease patients scored during endoscopy. The scoring is based on appearance of ulcers/sizing, % of ulcerative surface, % of affected surface, and if there were any narrowings or strictures found.</description>
          <population>Not enough subjects for analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Enrollment to 16 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Immunomodulator</title>
          <description>Azathioprine, 6 mercaptopurine or methotrexate.
Azathioprine: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past.
6 mercaptopurine: Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past as an alternative to imuran
Methotrexate: Medication will be given in subcutaneous injection form once a week if the patient cannot take imuran or 6 mercaptopurine.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study terminated early due to low subject enrollment. Since only 3 patients were enrolled, study analysis was not possible for measurable outcomes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Matthew Bohm, DO (Principal Investigator)</name_or_title>
      <organization>Indiana University</organization>
      <phone>3179485136</phone>
      <email>mbohm@iu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

